Navigation Links
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
Date:1/28/2010

SAN DIEGO, Jan. 28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients.  Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy.

"There is a significant unmet medical need in HCV patients who have not responded to pegylated interferon and ribavirin.  These patients often progress to cirrhosis, a life-threatening condition.  CTS-1027 has the potential to increase the effectiveness of the combination of pegylated interferon and ribavirin in this population," said Dr. Paul J. Pockros, Head, Division of Gastroenterology and Director of the SC Liver Research Consortium and The Scripps Clinic in La Jolla, CA.

CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. CTS-1027's anti-inflammatory and anti-fibrotic effects have been well-established in models of acute hepatitis and liver fibrosis. In addition, CTS-1027 has been shown to reduce and/or block HCV replication in in vitro preclinical models.  

This clinical trial is an open-label design testing an optimized dose of CTS-1027 in combination with Pegasys® and Copegus® in HCV-infected patients who were prior null responders to pegylated interferon and ribavirin treatment. Dosing will last for up to 48 weeks. The Company expects approximately 60 patients to be enrolled. The clinical trial will be conducted at up to fifteen medical centers in the U.S. Additional information about the trial can be found at:

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
2. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
3. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
4. Intercept Pharmaceuticals Raises $25 Million Series B Financing
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Amylin Pharmaceuticals to Webcast Year-End Financial Results
7. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
8. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
9. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
10. Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms
11. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... LONGMONT, Colo. , Aug. 27, 2015 /PRNewswire/ ... focused on the development of Next Generation ... for applications in high speed fiber-optic data ... Michael Lebby has been appointed to ... Lebby,s reputation in the field of optoelectronics is ...
(Date:8/27/2015)... and SOUTH SAN FRANCISCO, Calif. ... Fibrosis Foundation (PFF) and Veracyte, Inc. ... organizations are partnering on a U.S. patient survey ... interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis ... survey will assess the steps and time required ...
(Date:8/27/2015)... , Aug. 27, 2015  QB3@953—a ... a University of California (UC) research institute and ... company GSK to identify and facilitate collaborations to ... benefit patients. The agreement formalizes a ... Academia (DPAc) team and creates a new channel ...
Breaking Medicine Technology:Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... Md., Sept. 13, 2011 Sodexo, Inc., a leader ... with Healthsense, Inc.  As a part of the agreement, ... existing senior living client communities – expanding Sodexo,s current ... Life for all of the people and communities they ...
... University of Michigan Health System has selected a new system-wide ... medical to communications devices, wireless phones and pagers for its ... Hospital. "Moving from a facility where numerous beds ... where beds are now separated into multiple rooms, we anticipated ...
Cached Medicine Technology:Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 2Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 3New Hospitals to Implement New Communications Technology 2
(Date:8/27/2015)... ... August 27, 2015 , ... ... scheduled for October 27-29, 2015 in San Jose, CA. The first event ... focus on the void that exists where battery development and energy storage innovation ...
(Date:8/27/2015)... ... , ... In addition to its existing Doctor of Philosophy in Leadership and ... its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of ... nurses for the highest level of clinical nursing practice. , “Our vision is ...
(Date:8/27/2015)... ... ... North Pinellas, located at 1395 South Pinellas Avenue in Tarpon Springs, will open a free-standing ... located at US Highway 19 North and Highlands Boulevard, less than eight miles from the ... project is slated to begin in September 2015. , The new 24-bed facility ...
(Date:8/27/2015)... ... August 27, 2015 , ... NetDimensions is once again named ... the platforms required not only to effectively deliver, curate and administer great programs, but ... Inc. , For six consecutive years, NetDimensions has maintained its position on this ...
(Date:8/27/2015)... ... 27, 2015 , ... Z-Medica®, LLC, a leading developer and ... website http://www.Z-Medica.com , to further support the company’s corporate positioning. , The ... , “We launched a branded website last year to show our customers ...
Breaking Medicine News(10 mins):Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:Z-Medica® Launches New Corporate Website 2
... England, both in terms of lives and money nearly ... report published today by the All Party Parliamentary Group (APPG) ... Lives - concludes that, despite effective treatments, there are 365 ... with unnecessary seizures, and 74,000 people are taking anti-epilepsy drugs ...
... tentative agreement with Delmont Laboratory to introduce its immunotherapeutic ... . According to this initial agreement, Delmont Laboratory will ... manufactures for the final packaging in China. ... agreement is to be signed. This product requires a ...
... data from its Phase IIb study in Alzheimer's disease (AD) ... and treated as diabetes of the brain. ... of amyloid beta plaques in the brain, yet recent research ... the brains of mice gives rise to some of the ...
... Diagnostics today announces that it has completed its ... with BioVeris for approximately $600 million on April ... Diagnostics now owns the patents for Electrochemiluminescence (ECL) ... the human diagnostics field into new market segments ...
... confirmed that the potentially lethal H5N1 strain of bird flu ... the country, the second such incident here in a week. ... the area around Frohburg, near Liepzig, second incidence of the ... ,The discovery followed the confirmation on Sunday of ...
... that air pollution affects women more than men . ... groups of mice with pneumonia. One group was exposed ... filtered air. ,The exposure to ozone significantly ... compared to males, reported science portal SCIENCE A GoGo. ...
Cached Medicine News:Health News:Blunders in Epilepsy Care Cost Lives, and Money UK Report 2Health News:Experimental Drug Ketasyn(TM) (AC-1202) Treats Alzheimer's as Diabetes of the Brain 2